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Abstract
Background: The clinical and pathogenetic heterogeneity of Autism Spectrum Disorders (ASD) limits our ability to predict
its short- and long-term evolution. Aim of this naturalistic study was to observe the clinical evolution of very young children
with ASD for 12 months after first diagnosis, in order to identify those children who might develop a more positive
trajectory and understand how a wide range of biological, clinical and familial factors can influence prognosis.
Methods: Ninety-two children were characterized in terms of family history, prenatal and perinatal variables, and clinical
conditions. The sample was divided into four subgroups based on the association of 22 biological, clinical and family
history variables. Developmental Quotient (DQ), determined using the Psychoeducational Profile Revised (PEP-R), and
symptoms severity, measured by means of the Autism Diagnostic Observation Schedule (ADOS), were evaluated at
baseline (T0) and after one year (T1), while receiving treatment as usual. Changes in DQ and ADOS between baseline and
follow-up and differences in the short-term evolution of the four subgroups were analyzed.
Results: At T1, 55.4 % of the children demonstrated some gains either of autistic symptomatology or of developmental
skills. Mean ADOS score was 13.63 ± 3.67 at T0 and 10.85 ± 4.10 at T1 and mean DQ was 0.64 ± 0.14 at T0 and 0.66 ± 0.
15 at T1. At follow-up, 33.7 % of the children showed an improvement in DQ and 37 % presented a less severe
symptomatology, measured by means of ADOS. Overall, 15.2 % of the sample displayed major improvements both on
developmental quotient and ADOS severity score; these children presented less EEG abnormalities and familial
psychiatric disorders. The four subgroups, based on biological, clinical and familial variables, showed differing trends in
terms of evolution.
Conclusions: Categorizing very young children with ASD in terms of biological, clinical and familial variables can be
instrumental in predicting short-term evolution. This exploratory study highlights the importance of a precise
characterization and thorough analysis of interactions among biological and clinical variables, in order to predict the
developmental evolution in children with ASD.
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Background
Autism Spectrum Disorders (ASD) are a group of hetero-
geneous neurodevelopmental conditions, characterized by
persisting deficits in social communication and interaction
in multiple contexts, as well as restricted, repetitive pat-
terns of interests or activities [1]. ASD, affecting up to 1
every 100 school-age children, are considered to be an
umbrella condition, characterized by specific genetic and
biological underpinnings, significant heterogeneity in clin-
ical presentation, different short- and long-term evolution
and, possibly, diversified response to interventions [1, 2].
These disorders are determined by neurobiological ab-
normalities, as atypical brain development and alterations
in synapses formation and connectivity [1]. Studies of gen-
etic and epigenetic factors have suggested a polygenic
nature of these conditions, but in most cases the exact na-
ture of ASD’s aetiology remains elusive [2, 3]. Actually, in
only 10–20 % of cases is possible to identify a syndromic
* Correspondence: curatolo@uniroma2.it
2Department of Neuroscience, Pediatric Neurology Unit, University of Rome
“Tor Vergata”, via Montpellier 1, 00133 Rome, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Emberti Gialloreti et al. Italian Journal of Pediatrics  (2016) 42:70 
DOI 10.1186/s13052-016-0281-4
form of autism related to a specific medical or genetic
syndrome [3, 4].
Somatic and psychiatric comorbidity are highly repre-
sented in ASD, due to the underlying abnormalities in
the biological pathways that can lead not only to alter-
ations of the central nervous system, but also to systemic
signs and symptoms, immune dysregulation, and sensory
disturbances [5–7]. Although these symptoms are not
directly related to the core features of ASD, they might
have an important impact on the evolution and response
to interventions [8].
The core symptoms of ASD become evident in early
childhood. One of the major achievements in the last
few years is the possibility of early diagnosis, already be-
fore 18–24 months of life, through the identification of
specific signs and symptoms [1, 3]. Different studies
have confirmed the importance of early detection and,
therefore, early intervention for ASD children [9–11].
Some intervention approaches, mostly based on behav-
ioural and developmental principles, eg Applied Behav-
iour Analysis (ABA) or the Early Start Denver Model,
have been demonstrated to be efficacious in improving
both autistic symptoms and cognitive, language and
adaptive skills, at least in research settings and in some
subgroups of subjects [12–14]. Family involvement has
also been recommended as an efficacious component of
early intervention [15, 16]. However, none of these ap-
proaches has been proved to substantially modify the
diagnosis or natural course of ASD, which continue to
be considered life-long disorders.
Actually, the clinical and pathogenetic heterogeneity of
the disorder limits our ability to predict its short- and
long-term evolution and may contribute to the current
lack of effectiveness and to the variability in response to
interventions that is observed across all evidence-based
approaches [17, 18]. The heterogeneity and developmen-
tal nature of the disorder make it unlikely that one spe-
cific intervention will be best for all children with ASD
and several researches point to the inadequacy of one
single approach for all affected individuals [9, 19].
Some authors have attempted to identify biological
subtypes of ASD, homogeneous in terms of clinical pres-
entation and/or underlying pathogenesis, but few studies
have analysed possible relationships between potential
predicting factors and ASD evolution [20–22]. Baseline
cognitive and language abilities are the most often re-
ported correlates of positive developmental trajectories
of children with ASD [10, 14]. Other studies have also
identified more specific abilities associated with positive
outcomes, including play skills, joint attention, imitation
and low social avoidance; however, not all studies concur
with these conclusions [17, 19]. In terms of clinical fac-
tors, several researches have demonstrated that children
with any medical/genetic condition, including epilepsy,
as well as children with a history of regression, had often
the worst outcomes at long term follow-up [3, 8, 19]. It
is plain that understanding how ASD unfold would be
critical to better identify intervention goals and predict
its evolution.
A multicentre autism consortium study has recently
analysed the different autistic phenotypes by taking into
account several developmental, clinical, and family his-
tory variables, including biological components [5, 7]. In
the present study, we aimed to evaluate and understand
if some specific biological and clinical factors could be
helpful predictors of short-term evolution in a popula-
tion of young children with ASD.
Methods
Design of the study
In this naturalistic longitudinal observational study, we
distributed a sample of young children with ASD into
four subgroups, according to the main characteristics of
each child previously identified by means of principal
components analysis performed and published by Sacco
et al. [5]. Principal components analysis is a mathemat-
ical procedure that transforms a number of variables, re-
trieved from a large set of data, into a small number of
uncorrelated variables called principal components. Its
goal is to reduce the dimensionality of the data set, with
a minimal loss of information, so to express the data in
such a way as to highlight their similarities and differ-
ences. The first principal component accounts for as
much of the variability in the data as possible, and each
succeeding component accounts for as much of the
remaining variability as possible [23].
In the study reported by Sacco and co-workers, princi-
pal component analysis has been used, in a sample of
people with ASD, to try to reduce 22 possible outcome
predictors into a small number of components, while
minimizing the loss of information. The 22 biological,
clinical, and family history variables included in the ana-
lysis, which eventually identified four subgroups, are
presented in Table 1. As a result of the principal compo-
nent analysis, each subgroup was characterized by a
prevalent, though not unique, feature: (I) disruption of
the sleep–wake cycle associated with hyperactivity and
sensory abnormalities (CS), (II) immune dysregulation,
associated with prenatal obstetric complications (ID),
(III) generalized neurodevelopmental delay (ND), and
(IV) stereotypies and abnormal early social behaviours
(SB) [5]. In our study we aimed to evaluate if these four
principal components were able to predict the outcome
of a population of young ASD children 12 months after
their first diagnosis.
In order to possibly enlarge the informative value of
these components, we added also data about the co-
presence of other clinical/medical conditions of the child
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or of his/her first-degree relatives. We chose a pretest-
posttest design in order to follow the development of
the sample and to determine potential correlations be-
tween some specific factors and short-term evolution. All
patients received their first diagnosis and were evaluated
at baseline (T0) in the outpatient clinic of the Pediatric
Neurology Unit of the University of Rome “Tor Vergata”,
in order to determine clinical characteristics, developmen-
tal level, and symptom severity. Participants were re-
examined one year after their first evaluation (T1).
Participants
One hundred two children with a diagnosis of ASD were
consecutively recruited in the study. To be included in the
present study, children had to receive an ASD diagnosis
by two independent child neurologists of our research
team, according to the ‘Italian guidelines on ASD manage-
ment’ [24]. Enrolment took place from January to July
2014, a time in which DSM-V was not yet available in
Italy. For this reason, we have used the diagnostic criteria
based on the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) for the diagnosis of
Autism Spectrum Disorders and we have included Autis-
tic Disorder (AD), Pervasive Developmental Disorder Not
Otherwise Specified (PDD-NOS) and Asperger Syndrome
(AS). We have used the DSM-IV criteria also at the time
of follow up, in order to guarantee a homogeneous diag-
nostic classification of the sample.
Exclusion criteria of the study included (1) neurodeve-
lopmental disorders of known aetiology (eg Fragile X
Syndrome, Tuberous Sclerosis, or known chromosomal
abnormalities or metabolic disorders), (2) significant
sensory or motor impairment, and (3) serious chronic
diseases. We did not consider epilepsy as an exclusion
criterion; nevertheless, no child had seizures or suffered
from epilepsy at the time of enrolment. Furthermore, at
T0 no child was under pharmacological treatment.
Out of the 102 considered children, 5 were excluded
because they were affected by medical conditions with a
significant sensory or motor impairment that could in-
fluence the children’s ability to complete the whole diag-
nostic assessment; specifically, four of them were
excluded for the presence of significant hearing and/or
vision impairments, and one child was excluded for the
presence of a major motor disability due to Duchenne
dystrophy. Other 5 children were identified as poten-
tially eligible, but their families did not agree to partici-
pate in the study. Consequently, 92 children (84 boys
and 8 girls) were eventually enrolled in the study.
Clinical assessment
All children were examined both at baseline (T0) and at
follow-up (T1). In addition, at T0 all patients underwent
a defined medical workup, including neurological exam-
ination, awake/sleep EEG, as well as height, weight and
head circumference measurement. The retrieved data
were completed by examining their medical records.
Clinical assessment of the children included two differ-
ent areas: (1) The administration of developmental and
symptomatological tests and (2) the collection of the
child’s medical history. The diagnostic protocol included
the administration of the Psychoeducational Profile Re-
vised (PEP-R) for the identification of both global devel-
opmental level and specific profiles of the six PEP-R
sub-items: cognitive abilities, expressive language, recep-
tive language, gross-motor abilities, fine-motor abilities,
and visual-motor imitation [25]. The PEP-R is widely
used in clinical settings and its utility has been extended
to research work to describe clinical features and short-
term evolution of children with ASD. Although the PEP-
Table 1 Biological, clinical, and family history variables included in the analysis, which eventually identified the four subgroups used
in the study (from Sacco et al. 2010)
Developmental and clinical variables Biological variables Family history variables
Age at non-verbal language development History of allergies Pregnancy duration
Age at verbal language development History of regression History of obstetric complications
or recurrent spontaneous abortions
in the mother
Level of verbal language development History of obstetric complications
at or immediately after birth
History of any allergic and/or immune
disease in the family
Age at walking History of any infectious disease
at autism onset
History of tumors in the family
Age at acquisition of bladder control at night History of sleep disorders History of any neurological or psychiatric
disorders in the family
Age at first social smile Presence of muscle hypotonia at
neurological examination
Motor, verbal or vocal stereotypies EEG pattern (evaluated at T0)
Self-aggressive or self-injurious behaviour Pain sensitivity (reported by parents)
Hyperactivity
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R was not originally designed to determine general level
of intellectual functioning, several studies have suggested
that this test demonstrates a good internal consistency
and inter-rater reliability, provides a good estimate of
cognitive abilities in young children with autism and/or
other disabilities, and is a sensitive pre-post measure for
the evaluation of clinical evolution [26, 27].
The Autism Diagnostic Observation Schedule (ADOS)
was administered to confirm diagnosis and to determine
the severity of autistic symptoms [28]. In addition, the
Autism Diagnostic Interview-Revised (ADI-R) was also
used to confirm the diagnosis at T0 [29].
Two different child neurologists of our research team,
which are expert in the diagnostic management of young
children with ASD, were involved in the administration
of the various parts of the diagnostic protocol. Both
evaluators were blind to the study hypotheses. One as-
sessor administered the PEP-R at T0 to determine the
Developmental Quotient/Intelligence Quotient (DQ)
and the developmental profile in the six PEP-R sub-
items. One year later, PEP-R was re-administered by the
same assessor in order to re-establish the child’s DQ in
all six areas of the scale.
The ADOS was administered both at T0 and T1 by an-
other assessor of our research team, which had completed
the ADOS training and is in possession of an ADOS re-
search certification. According to the child’s language
level, the examiner used module 1 (minimal to no lan-
guage) for the evaluation of 80 children, and module 2
(non-echoed phrase speech) for the other 12 children.
The whole sample was tested with the two instruments
at T0 and T1. For the PEP-R scale, the entire protocol
was administered in one or two sessions, depending on
the cooperation of the child. All children were able to
complete their level of functioning diagnostic assess-
ment. Moreover, the two assessors collected the clinical
data of medical history of the enrolled children and su-
pervised their medical workup.
The recording of the medical history of the children
encompassed family history variables (parental and first-
degree relative diseases, history of obstetric complications
or recurrent spontaneous abortions in the mother, neuro-
psychological disorders in parents and/or siblings), prenatal
or perinatal variables (pregnancy course, pharmacological
treatment or infections during gestation, birth weight, peri-
natal complications), and information about the presence
of clinical conditions in the affected individuals, ie, history
of regression (defined as loss of more than five spoken
words used communicatively), sleep disorders, history of al-
lergies, and gastrointestinal disorders. The socio-economic
status of the family was categorized into lower-, middle-,
and upper-class, based on the family annual revenue share
and parental level of education, in accordance with the cri-
teria of the Italian Statistical Bureau (ISTAT) [30].
Measurement of the changes over time
To evaluate the evolution after one year (T1) we used
two measures: ‘Change of DQ rate’ and ‘change of ADOS
diagnostic scores’. We analysed the two measures both
independently and related to one another.
Regarding DQ values, we set the threshold for change in
developmental level as an increase/decrease of 5 % DQ
score and then we generated three groups: ‘DQ improved
group’ for those patients whose DQ level raised from T0 to
T1 by at least 5 %; ‘DQ worsened group’ for those patients
whose DQ level decreased by at least 5 %; and ‘DQ stable
group’ for those patients with a DQ change of less than 5 %.
Regarding changes in ADOS scores, subjects have
been dichotomized into two groups. Those subjects,
whose ADOS composite score improved between T0
and T1 were included in the “ADOS Improvement
group”. The others were included in the “ADOS No-
improvement group”. We used also the Calibrated
Severity Score (CSS) and the change of the ADOS classi-
fication category as two secondary measures of quantita-
tive and qualitative symptomatological changes. The
CSS is a standardized score of the relative severity of
autism-specific behaviours; this measure has been cre-
ated by Gotham and co-workers to compare autistic
symptoms within and across individuals of different ages
[31]. We included CSS among the measures of symp-
tomatological change because it is less influenced by age
and developmental level than the ADOS raw totals.
Interventions
Aim of this study was not to investigate or to compare
the efficacy of different interventions. Nevertheless, all
the included children underwent some form of interven-
tion during the follow-up period. As it is common in the
Italian public health system, interventions did not take
place at our centre, but families have been referred to
community rehabilitation centres. The modality of
community-based treatment follows the ‘Italian guide-
lines on ASD management’ [24]. In Italy, treatment as
usual is composed of specific interventions performed
by child neuropsychiatric services (CNS) and of school
inclusion activities. In terms of school inclusion strat-
egies, the Italian programs are based on a co-teaching
model in which students with and without disabilities
work together in the same classroom; children with dis-
abilities are also trained by a “support teacher” and
benefit from an individualized educational plan [11].
Intervention models offered by the local health ser-
vices include sessions of individual psychomotricity and/
or speech and/or psycho-educative therapy. Each child
had an individualized treatment plan that incorporated a
range of objectives, dependent on the child’s level of
functioning, but, as a matter of fact, it is mainly based
on staff expertise rather than standardized treatment
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protocols. All interventions were delivered by therapists
and implemented also in familial and school settings.
Treatments as usual can be located in the behavioural/
developmental continuum, from highly structured behav-
ioural approaches, guided by a therapist, to approaches
that follow the interests of the child in a naturalistic set-
ting; this model is always based on individualization to
each infant’s developmental profile and focused on a
broad range of learning targets. In several cases, treatment
as usual includes a number of hours of parent coaching or
parent involvement during the child–therapist work ses-
sions, in order to support parental sensitivity to child cues
and to implement intervention targets with their child
during and outside of the sessions [15, 32].
In our study, mean age at start of treatment as usual
was 38.1 ± 7.8 months. The participating children received
treatment as usual for a mean of 10.7 h per week, includ-
ing hours of individual sessions and school inclusion.
Statistical analysis
Changes between baseline and follow-up were evaluated
with paired samples t tests or chi-square tests. Differences
between groups were analysed by means of t-tests for inde-
pendent samples, ANOVA models, Pearson’s Chi-squared
tests, or Fishers Exact tests (for small groups). Spearman’s
rho correlation coefficients were used to examine associa-
tions between quantitative measures. The effect sizes were
estimated by means of Cohen’s d. We always applied a sig-
nificance level of 0.05, Bonferroni-corrected for multiple
comparisons. We decided to use the more stringent
Bonferroni correction given the high number of statistical
comparisons included in the study to guard against Type I
errors. Results are reported as means ± SDs. All analyses
were performed using R Language and Environment for
Statistical Computing programme (http://www.R-projec-
t.org; accessed April 2016) [33].
Ethics
All performed procedures were in accordance with the
ethical standards of the institutional and national re-
search committee and with the 1964 Helsinki declar-
ation and its later amendments [34]. Informed consent
to the participation in the research and to the publica-
tion of patients’ data was obtained from the parents or
legal guardian of all individuals included in the study (all
children were under age 16). Study procedures were ap-
proved by our research ethics committee.
Results
Distribution of clinical features and medical variables in
the whole sample
Clinical features
Ninety-two children (84 boys and 8 girls), whose age at
baseline ranged from 18 to 50 months, were enrolled in
the study. At T0, mean age of the participating children
was 36.9 ± 7.6 months. Female/male ratio was 1:9. In
terms of developmental characteristics, measured by
means of the PEP-R, mean developmental age was 23.4
± 6.8 months and mean developmental quotient (DQ)
was 0.64 ± 0.14. Concerning language skills at T0, 58.7 %
of the children were nonverbal, while 31.5 % used single
words, and 9.8 % used phrases. In terms of symptomato-
logical severity, according to ADOS cut-offs at baseline,
49 children have been identified as PDD-NOS, 39 as
AD, and 4 as non-autism. After thorough analysis and
discussion between the two child neurologists, the latter
four children have been nevertheless included in the
study as they had been clinically diagnosed as PDD-
NOS, according to the DSM-IV criteria and the Italian
guidelines. Table 2 summarizes the basic demographic
and clinical features of the sample.
Clinical and medical history variables
Thirty-six children (39.1 %) had a history of allergic dis-
orders, 23 (25.0 %) had a positive history for regression,
15 (16.3 %) presented macrosomy, 9 (9.8 %) had EEG al-
terations, 27 (29.3 %) presented with sleep problems in
their case history.
No patient began a pharmacological treatment or de-
veloped seizures or any further neurological condition
during the follow-up time.
Family factors
In terms of familial risk factors, 56.5 % of the families re-
ported neurological or psychiatric disorders in one or
more first-degree relatives. Twenty-five families (27.2 %)
were categorized as upper-class, 57 (62 %) as middle-
class and 10 (10.8 %) as lower-class.
Table 2 Basic characteristics of the sample
N (Percent)
Females 8 (8.7 %)
Males 84 (91.3 %)
Mean ± SD
Chronological age (months) at T0 36.9 ± 7.6
Chronological age (months) at T1 49.3 ± 7.7
Diagnosis based on ADOS cut-offs at T0 N (Percent)
Autism Spectrum Disorder 49 (53.3 %)
Autism 39 (42.4 %)
Non Autism 4 (4.3 %)
Mean ± SD
Developmental age (months) measured
by PEP-R at T0
23.4 ± 6.8
Developmental age (months) measured
by PEP-R at T1
32.6 ± 9.0
N = 92, ADOS Autism Diagnostic Observation Schedule, PEP-R
Psychoeducational Profile Revised
Emberti Gialloreti et al. Italian Journal of Pediatrics  (2016) 42:70 Page 5 of 13
Individual clinical features at T0 and T1
Mean chronological age of the participating children was
36.9 ± 7.6 at baseline (T0) and 49.3 ± 7.7 at follow-up
(T1). Mean developmental age, tested using the PEP-R
scale, was 23.4 ± 6.8 at T0 and 32.6 ± 9.0 at T1. Mean
developmental quotient (DQ) was 0.64 ± 0.14 at T0 and
0.66 ± 0.15 at T1. Mean ADOS composite score was
13.63 ± 3.67 at T0 (Median: 14) and 10.85 ± 4.10 at T1
(Median: 11). The overall difference of ADOS score be-
tween T0 and T1 was -2.78 ± 3.98, ie, an average im-
provement of 11.6 %. After one year of follow-up we
observed also a significant score decrease in terms of
CSS (p < 0.001). Biological, clinical, and family history
variables included in the analysis, which eventually iden-
tified the four subgroups used in the study, have been
previously described in Table 1.
Short-term evolution of the whole sample
Mean duration of follow-up was 12.4 ± 2.3 months.
Change in Developmental Quotient
At T1, 31 children (33.7 %) have been included in the
‘DQ improved group’, 41 in the ‘DQ stable group’
(44.6 %), and 20 (21.7 %) in the ‘DQ worsened group’.
Overall, DQ values showed a statistically significant in-
crease (p < 0.01) with respect to baseline measures. The
analysis of PEP-R sub-quotients showed a considerable
change especially in the cognitive (p < 0.0001), receptive
(p < 0.05), and expressive language (p < 0.01) areas; con-
versely, visual-motor imitation, gross-motor and fine-
motor areas remained substantially stationary.
Changes in ADOS diagnostic scores
At T1, ADOS improved in 69 (75.0 %) children (Im-
provers), whereas it was the same or worse in 23 (25.0 %)
children (Non-Improvers). Interestingly, the “ADOS Im-
provers group” had a significantly (p < 0.004; Cohen’s d:
0.71) higher ADOS score at baseline (14.24 ± 3.58) com-
pared to the “ADOS Non-Improvers group” (11.74 ±
3.35). On the other hand, ADOS score at T1 was 9.78 ±
3.85 among “ADOS Improvers” and 14.04 ± 3.10 among
“ADOS Non-Improvers” (p < 0.0001; Cohen’s d: 1.11). On
average, “ADOS Improvers” ameliorated by 4.48 ± 2.89
points, compared to the “ADOS Non-Improvers” who
worsened by 2.30 ± 1.94 points. In other words, those who
fared worse at baseline tended to improve more. Analo-
gously, also CSS at T0 (5.51 ± 1.51 vs. 4.83 ± 1.03; p < 0.05;
Cohen’s d: 0.45) and at T1 (4.10 ± 1.43 vs. 5.74 ± 0.62; p <
0.0001; Cohen’s d: 1.15) was significantly different between
“ADOS Improvers” and “ADOS Non-Improvers”. In order
to analyse ASD severity modifications, we used change in
ADOS categories (from ‘autism’ to ‘autism spectrum’ or
‘non-autism’, and from ‘autism spectrum’ to ‘non autism’).
At T1, 34 children (37.0 %) modified their ADOS
classification in a less severe category; on the other
hand, 42 children (45.6 %) remained stable and 16
(17.4 %) were included in a more severe category (from
‘non autism’ to ‘autism spectrum’ or ‘autism’; from
‘autism spectrum’ to ‘autism’). Further results are pre-
sented in Table 3.
Correlation between changes in ADOS scores and DQ
No significant differences have been observed between
“ADOS Improvers” and “ADOS Non-Improvers” in
terms of Global DQ at T0 (0.63 ± 0.14 vs. 0.62 ± 0.12;
Cohen’s d: 0.07) or at T1 (0.67 ± 0.16 vs. 0.64 ± 0.14;
Table 3 Clinical measures of the whole sample at T0 and T1,
and number of children who improved in the different domains
M ± SD
T0 T1 p
ADOS composite 13.63 ± 3.67 10.85 ± 4.10 <0.0001
A 4.72 ± 1.74 3.39 ± 1.75 <0.001
B 8.91 ± 2.27 7.46 ± 2.79 <0.0001
C 2.86 ± 1.11 2.39 ± 1.28 <0.01
D 3.71 ± 1.56 3.17 ± 1.75 <0.01
CSS 5.34 ± 1.44 4.51 ± 1.46 <0.0001
DQ 0.64 ± 0.14 0.66 ± 0.15 <0.01
DQ sub-quotients:
Cognitive abilities 0.72 ± 0.19 0.77 ± 0.21 <0.0001
Expressive language 0.44 ± 0.16 0.47 ± 0.19 <0.05
Receptive language 0.52 ± 0.18 0.57 ± 0.23 <0.01
Fine motor abilities 0.73 ± 0.15 0.73 ± 0.17 =0.915
Gross motor abilities 0.78 ± 0.16 0.78 ± 0.17 =0.799
Visual motor imitation 0.68 ± 0.15 0.68 ± 0.14 =0.964
Number (Percent)
Improvement in both ADOS
























N = 92; ADOS Autism Diagnostic Observation Schedule, CSS Calibrate Severity
Score, DQ Developmental Quotient, Statistically significant results are in bold
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Cohen’s d: 0.20). No other statistically significant differ-
ences were demonstrated by the analysis of the correl-
ation between the two measures.
According to the definition of positive evolution, about
55.4 % of the participants showed a clinical improvement
at follow-up, although it appeared to be partial and linked
only to one measure (either ADOS or DQ) in 40.2 % of
our children. There was no statistically significant associ-
ation between severity decrease, measured by means of
ADOS, and improvement of DQ levels. This means that
not all children that showed a positive change in one
measure improved necessarily also in the other one.
Short-term evolution of the “Major Improvers” group
Fourteen children (15.2 %) displayed a significant im-
provement both of developmental level and symptoms
severity. We have labelled this subgroup as ‘Major Im-
provers’ and we conducted a more detailed analysis of
these patients, in order to understand if this particular
subclass showed different features and/or phenotypes,
which might explain a better evolution at follow-up.
Considering individual pre-treatment features, the
level of verbal-language skills was higher, though not sig-
nificantly, for children in the ‘Major Improvers’ group,
compared to the others (35.7 % of children without ver-
bal language vs. 65.9 %).
In terms of associated medical variables, the analysis
found that ‘Major Improvers’, compared to those who
worsened both at ADOS and DQ, presented with a posi-
tive- although non statistically significant - tendency not
to have EEG abnormalities (0 % vs. 12.2 %), not to have
allergic disorders (28.6 % vs. 44.0 %), not to belong to a
family with low socioeconomic status (0 % vs. 14.6 %).
With respect to familial factors, the occurrence of
neurological or psychiatric disorders, even if not statisti-
cally significant, was lower in the ‘Major Improvers’ fam-
ilies (50.0 %) than in those who improved neither in
symptomatology nor in developmental quotient (63.4 %).
Biological components and associated clinical predictors
in the four subgroups
Lastly, we stratified all participants based on the four
previously identified subgroups and evaluated potential
associations between their evolution and belonging to a
specific subgroup. Twenty-four children (26.1 %) were
classified in the CS subgroup, 31 (33.7 %) in the ID sub-
group, 9 (9.8 %) in the ND subgroup, and 28 (30.4 %) in
the SB subgroup. Table 4 provides an overview of the
medical and clinical variables of the four subgroups. In
terms of demographic, medical, and/or co-morbid condi-
tions, we did not observe significant differences among
the four subgroups, except for those already considered as
attribution criteria to a specific subgroup (eg a significant
difference in sleep disorders for the ‘circadian and sensory
dysfunction’ CS subgroup, or in pre/perinatal complica-
tions for the ‘immune dysfunction’ ID subgroup).
DQ and ADOS scores in the four subgroups at T0
In terms of global DQ at baseline, lower DQ values were
significantly associated with the inclusion in the ND
subgroup (p < 0.0001). Specifically, mean DQ level at T0
was 0.61 ± 0.12, 0.62 ± 0.13, 0.73 ± 0.12, and 0.50 ± 0.09
in the CS, ID, SB, and ND subgroups, respectively. Con-
versely, the individual core of ASD features, measured at
T0 by means of the ADOS score, did not show statisti-
cally significant differences between the four subgroups
(13.79 ± 3.61, 13.84 ± 3.83, 12.50 ± 3.28, and 16.00 ± 3.64,
in the CS, ID, SB, and ND subgroups, respectively).
Nevertheless, there is a tendency of the SB subgroup to
manifest a lower ADOS composite score, compared to
the three other subgroups. On the other hand, the ND
subgroup was characterized by a greater symptomatolog-
ical severity, albeit also this difference was not statisti-
cally significant. There were no significant differences
between the four subgroups on any familial variable.
Change of DQ and ADOS scores in the four subgroups
between T0 and T1
With respect to modifications of the DQ rate and ADOS
category, we found a few statistically significant associations
between a positive evolution and belonging to a specific
biological subgroup (see Table 5 and Fig. 1 for details).
Concerning global DQ values, none of the four sub-
groups showed a statistically significant change between
T0 and T1. Overall, the independent analysis of PEP-R
sub-areas revealed a substantial stability of all develop-
mental skills, however, the CS subgroup showed a sig-
nificant improvement in the cognitive area (p < 0.05) and
the SB subgroup presented with a statistically significant
higher expressive and receptive language level (p < 0.05).
Also the total rate of the ADOS composite score dif-
fered significantly between T0 and T1 for the CS, ID
and SB subgroups, suggesting an improvement of symp-
toms severity. Particularly, the CS subgroup displayed a
significantly lower score in ‘Language and Communica-
tion’ and ‘Stereotyped Behaviours and Restricted Inter-
est’; the SB subgroup showed a marked improvement in
all sub-areas, except in the ‘Play’ item, while the ID sub-
group ameliorated symptomatological levels in ‘Lan-
guage and Communication’, ‘Social Interaction’ and ‘Play’,
but not in ‘Stereotyped behaviours and Restricted Inter-
est’. On the other hand, the ND subgroup did not reach
any significant improvement in any ADOS sub-area.
Discussion
In this study, we classified 92 young children with ASD
into four subgroups, according to their biological, med-
ical and family history characteristics; we observed their
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evolution for 12 months after first diagnosis, in order to
identify those children who might develop a more positive
trajectory and understand how a wide range of biological,
medical and clinical factors might influence evolution.
After one year of follow-up, more than half of the
study participants obtained some gains either in terms
of autism severity or of developmental skills. Moreover,
our study demonstrated that even in such a brief period
of observation 15 % of the sample, defined as ‘Major Im-
provers’, showed significant advances on standard scores
of autism severity, adaptive behaviours and developmen-
tal level. The ‘Major Improvers’ showed a positive ten-
dency, although non-statistically significant, to present
less EEG abnormalities and less psychiatric disorders in
their family history compared to the ‘Non Improvers
group’. Notwithstanding the lack of a statistically signifi-
cant improvement, we believe that it is meaningful to
describe such a tendency, as previous studies on devel-
opmental trajectories have revealed the existence of a
particular category of children, identified as “bloomers”
or “accelerated”, characterized by a quick improvement
over time, possibly representing a sort of neurobiological
and genetically protected category [3, 35, 36]. On the
other hand, it has been demonstrated that autistic chil-
dren with some medical conditions, history of seizures,
and severe intellectual disability are more likely not to
improve over time [19, 37].
The variability in terms of developmental evolution ob-
served in different studies probably reflects the heterogen-
eity of ASD samples. In our study the univariate analysis
of the different variables lead only to a few statistically sig-
nificant results. As a matter of fact, given the complexity
of the biological underpinning of ASD, current knowledge
of factors affecting its evolution is limited, and single be-
havioural or biological predictors may not be sufficient to
correctly foretell upshots [38, 39].
For this reason, we tried to identify some biological
subgroups as well, so to outline if the combination of
different biological components, and not only a single
factor, might be associated with a specific developmental
course. We therefore identified, by means of principal
component analysis, four subgroups characterized by a
prevalent - though not unique - feature, based on the as-
sociation of 22 biological, clinical and family history vari-
ables [5]. In this way, each child was included in one of
the four subgroups. In terms of the potential correlation
between belonging to a subgroup and having a specific
developmental profile or global DQ values, we observed
that the four subgroups showed at follow-up a substan-
tial stability of all developmental skills and DQ scores;
however, we observed also that belonging to a subgroup
was associated with a positive trend in some specific skill
areas: the ‘circadian and sensory dysfunction’ subgroup
showed a significant improvement in the cognitive area,
while the ‘stereotypic behaviour’ subgroup presented
with a higher expressive and receptive language level at
follow-up. Also in terms of symptomatological changes,
the ‘circadian and sensory dysfunction’ subgroup fared
better in language, communication, and stereotyped be-
haviours, while the ‘stereotypic behaviour’ subgroup im-
proved in all these sub-areas. The ‘immune dysfunction’
subgroup ameliorated in language and social interaction,
but not in terms of stereotyped behaviours. Overall, we
observed positive trends, particularly in the ‘stereotypic
behaviour’ subgroup, and negative trends mainly in the
‘neurodevelopmental delay’ subgroup. These observa-
tions – even though exploratory and preliminary - are,
in our knowledge, among the first ones to suggest using
multiple biological, clinical and familial factors as predic-
tors of evolution.
There are several limitations of this study. Firstly, we
could not compare the eclectic, non-standardized inter-
vention approaches, which characterize treatment as
usual in Italy. Hence, we were unable to make any hy-
pothesis regarding which specific treatment ingredient
was leading to a better outcome. In addition, the
Table 4 Medical complaints and familial factors of the four subgroups at T0
CS (N = 24) ID (N = 31) ND (N = 9) SB (N = 28)
Number (%) Number (%) Number (%) Number (%) p
EEG abnormalities 3/24 (12.5 %) 2/31 (6.5 %) 2/9 (22.2 %) 2/28 (7.1 %) =0.495
History of gastrointestinal disorders 13/24 (54.2 %) 18/31 (58.1 %) 5/9 (55.6 %) 7/28 (25.0 %) <0.05
History of allergies 14/24 (58.3 %) 15/31 (48.4 %) 1/9 (11.1 %) 6/28 (21.4 %) <0.01
History of sleep disorders 12/24 (50.0 %) 9/31 (29.0 %) 3/9 (33.3 %) 3/28 (10.7 %) <0.05
Prenatal, perinatak or postnatal complications 8/24 (33.3 %) 25/31 (80.6 %) 4/9 (44.4 %) 8/28 (28.6 %) <0.001
Macrocrania 1/24 (4.2 %) 7/31 (22.6 %) 3/9 (33.3 %) 4/28 (14.3 %) =0.107
History of regression 8/24 (33.3 %) 5/31 (16.1 %) 4/9 (44.4 %) 6/28 (21.4 %) =0.243
Family history of psycho-neurological disorders 16/24 (66.7 %) 17/31 (54.8 %) 3/9 (33.3 %) 16/28 (57.1 %) =0.399
Family history of tumors 3/24 (12.5 %) 5/31 (16.1 %) 2/9 (22.2 %) 3/28 (10.7 %) =0.817
CS Circadian and sensory dysfunction subgroup, ID Immune dysfunction subgroup, ND Neurodevelopmental delay subgroup, SB Stereotypic behaviour subgroup;
Statistically significant results are in bold
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Table 5 Clinical measures of the evolution for the four subgroups at T0 and T1
CS (N = 24) ID (N = 31) ND (N = 9) SB (N = 28)
T0 T1 p T0 T1 p T0 T1 p T0 T1 p
ADOS composite 13.79 ± 3.61 11.58 ± 3.82 <0.05 13.84 ± 3.83 11.23 ± 4.01 <0.0001 16.00 ± 3.64 14.11 ± 3.55 =0.120 12.50 ± 3.28 8.75 ± 4.11 <0.001
A 4.88 ± 1.85 3.75 ± 1.65 <0.05 4.90 ± 1.68 3.35 ± 1.58 <0.0001 5.44 ± 2.01 4.78 ± 1.48 =0.373 4.14 ± 1.53 2.68 ± 1.83 <0.001
B 8.92 ± 2.19 7.83 ± 2.58 =0.083 8.94 ± 2.41 7.87 ± 2.78 <0.01 10.56 ± 1.74 9.33 ± 2.29 =0.055 8.36 ± 2.18 6.07 ± 2.64 <0.01
C 2.67 ± 1.05 2.29 ± 1.27 =0.266 3.13 ± 1.09 2.48 ± 1.31 <0.01 3.44 ± 0.88 3.22 ± 1.30 =0.622 2.54 ± 1.14 2.11 ± 1.20 =0.089
D 3.92 ± 1.44 2.88 ± 1.62 <0.05 3.55 ± 1.67 3.52 ± 1.57 =0.903 4.44 ± 1.88 4.33 ± 2.06 =0.346 3.46 ± 1.40 2.68 ± 1.79 <0.01
CSS 5.58 ± 1.61 4.75 ± 1.36 <0.05 5.23 ± 1.63 4.68 ± 1.42 <0.05 5.56 ± 1.01 5.12 ± 1.05 =0.220 5.18 ± 1.19 3.93 ± 1.56 <0.01
Global DQ 0.61 ± 0.12 0.63 ± 0.11 =0.070 0.62 ± 0.13 0.65 ± 0.16 =0.190 0.50 ± 0.09 0.50 ± 0.07 =0.907 0.73 ± 0.12 0.76 ± 0.14 =0.060
Cognitive abilities 0.67 ± 0.17 0.73 ± 0.16 <0.05 0.71 ± 0.20 0.76 ± 0.20 =0.087 0.55 ± 0.10 0.55 ± 0.14 =0.855 0.82 ± 0.16 0.90 ± 0.19 =0.055
Expressive language 0.38 ± 0.08 0.42 ± 0.14 =0.163 0.41 ± 0.12 0.45 ± 0.18 =0.179 0.36 ± 0.08 0.29 ± 0.08 <0.05 0.53 ± 0.23 0.59 ± 0.21 <0.05
Receptive language 0.46 ± 0.15 0.48 ± 0.12 =0.342 0.49 ± 0.14 0.53 ± 0.21 =0.156 0.42 ± 0.08 0.38 ± 0.10 =0.110 0.64 ± 0.20 0.73 ± 0.26 <0.05
Fine motor abilities 0.70 ± 0.16 0.74 ± 0.14 =0.200 0.71 ± 0.14 0.71 ± 0.17 =0.733 0.59 ± 0.12 0.54 ± 0.07 =0.097 0.81 ± 0.12 0.81 ± 0.16 =0.995
Gross motor abilities 0.76 ± 0.18 0.81 ± 0.19 =0.332 0.77 ± 0.15 0.76 ± 0.16 =0.629 0.60 ± 0.14 0.62 ± 0.13 =0.721 0.86 ± 0.13 0.82 ± 0.17 =0.112
Visual motor imitation 0.66 ± 0.16 0.65 ± 0.10 =0.783 0.68 ± 0.14 0.70 ± 0.15 =0.448 0.55 ± 0.14 0.55 ± 0.09 =0.914 0.75 ± 0.11 0.73 ± 0.13 =0.586
CS Circadian and sensory dysfunction subgroup, ID Immune dysfunction subgroup, ND Neurodevelopmental delay subgroup, SB Stereotypic behaviour subgroup, ADOS Autism Diagnostic Observation Schedule, CSS
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heterogeneity of interventions received by the partici-
pants could have affected the interpretation of the re-
sults. In fact, we could not infer what proportion of the
evolution should be attributed to the intrinsic child’s
characteristics or environmental factors, rather than to
the intervention. In this view, the naturalistic ap-
proaches, contrary to RCTs, are not able to address the
question of the effectiveness of one specific intervention.
However, naturalistic studies allow evaluating real life
settings [11, 18]. Secondly, we analysed a large number
of factors in a fairly limited sample. Furthermore, as sev-
eral of the studied factors are related to each other and,
thus, can act both as independent variables and/or medi-
ators, it may be difficult to address causality. Moreover,
the intrinsic heterogeneity of the sample and the under-
representation of females may have affected the results.
Although this study highlighted some promising bio-
logical predicting factors, it did not consider all potential
factors. Therefore, the present study is exploratory; a
starting point to more accurate predictions. Our results
should be verified and confirmed by larger prospective
studies. It should also be mentioned that, although the
inter-rater reliability of the standardized tests are consid-
ered to be high and their objectivity in a naturalistic
clinical setting is well established, biases due to differing
raters cannot be entirely excluded [18, 39]. Lastly, we
observed evolution after one year of follow-up, hence,
our conclusions are limited only to short-term changes,
and cannot be automatically transposed to long-term
ones. Longer follow-up periods are needed to enlarge
the applicability of the results.
Notwithstanding these limitations, we believe that our
findings might be helpful to set up instruments that take
into account the considerable phenotypic variability of
ASD to predict the evolution of this disorder. Our study
highlights the importance of taking into account possible
predicting factors not as single variables, but always con-
sidering their interactions.
Conclusion
There is a paucity of studies that investigate biological
components associated with the developmental course
of young children with ASD. The needs of children with
ASD are complex and this is reflected in the diversified
evolutions, as well as measurement tools used to collect
evidence about the child’s progress. The heterogeneity of
evolutions in children with ASD compounds the
difficulty in understanding whether different aetiologies
are associated with differing phenotypic expressions and
short or long-term course. Moreover, current knowledge
of the factors associated with individual differences in
development is often limited to the analysis of specific
behavioural abilities and clinical studies are not designed
to consider the contribution of other potential risk fac-
tors, like the biological ones. The development of a more
detailed research methodology is mandatory to delineate
new specific clinical profiles or ASD subgroups and con-
sequently to better understand the critical difference be-
tween individual trajectories and group level evolutions.
In this view, the research on predictors of development,
including biological components, should be on top of
the ASD research agenda.
In our opinion, the results of the present study -
among the first ones to consider also biological predic-
tors - emphasize that taking into account a large number
of biological, clinical and familial factors can be useful to
better predict evolution. Adding other factors, not taken
into account by our exploratory study, will probably fur-
ther enhance our ability to foretell a child’s evolution. In
any case, our proof-of-concept study has highlighted
that only by analysing the multiple interactions of differ-
ent factors one can improve its capability to predict
ASD evolution at individual level. Indeed, in future we
should increasingly look at the clinical characteristics of
the children with ASD also from the perspective of their
possible interconnections with the many-sided bio-
logical, genetic and environmental factors.
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Fig. 1 Overview of the trends of the four subgroups from T0 to T1. The total rate of the ADOS composite score differed significantly at T0 and T1
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The independent analysis of PEP-R sub-areas revealed that the CS subgroup showed a significant improvement in the cognitive area and the SB
subgroup presented a higher expressive and receptive language level. CS: Circadian and sensory dysfunction subgroup; ID: Immune dysfunction
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